Format

Send to

Choose Destination
Nature. 2016 Oct 20;538(7625):388-391. doi: 10.1038/nature19815. Epub 2016 Oct 10.

Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts.

Author information

1
Institute for Biomedical Sciences, Shinshu University, Matsumoto 390-8621, Japan.
2
Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
3
Department of Cardiovascular Surgery, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
4
Department of Pediatrics, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
5
Ina Research Inc., Ina 399-4501, Japan.
6
Department of Molecular Life Science, Tokai University School of Medicine, Isehara 259-1193, Japan.
7
Brain Science Institute, Saitama University, Saitama 338-8570, Japan.
8
Graduate School of Science and Engineering, Saitama University, Saitama 338-8570, Japan.
9
Chromosome Engineering Research Center, Tottori University, Yonago 683-8503, Japan.
10
Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Kyoto 606-8501, Japan.

Abstract

Induced pluripotent stem cells (iPSCs) constitute a potential source of autologous patient-specific cardiomyocytes for cardiac repair, providing a major benefit over other sources of cells in terms of immune rejection. However, autologous transplantation has substantial challenges related to manufacturing and regulation. Although major histocompatibility complex (MHC)-matched allogeneic transplantation is a promising alternative strategy, few immunological studies have been carried out with iPSCs. Here we describe an allogeneic transplantation model established using the cynomolgus monkey (Macaca fascicularis), the MHC structure of which is identical to that of humans. Fibroblast-derived iPSCs were generated from a MHC haplotype (HT4) homozygous animal and subsequently differentiated into cardiomyocytes (iPSC-CMs). Five HT4 heterozygous monkeys were subjected to myocardial infarction followed by direct intra-myocardial injection of iPSC-CMs. The grafted cardiomyocytes survived for 12 weeks with no evidence of immune rejection in monkeys treated with clinically relevant doses of methylprednisolone and tacrolimus, and showed electrical coupling with host cardiomyocytes as assessed by use of the fluorescent calcium indicator G-CaMP7.09. Additionally, transplantation of the iPSC-CMs improved cardiac contractile function at 4 and 12 weeks after transplantation; however, the incidence of ventricular tachycardia was transiently, but significantly, increased when compared to vehicle-treated controls. Collectively, our data demonstrate that allogeneic iPSC-CM transplantation is sufficient to regenerate the infarcted non-human primate heart; however, further research to control post-transplant arrhythmias is necessary.

PMID:
27723741
DOI:
10.1038/nature19815
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center